US warns of cancer-agent in Japan weight loss pills

The US Food and Drug Administration on Tuesday warned consumers not to take a product called "Japan Rapid Weight Loss Diet Pills" because they contain a suspected cancer-causing agent.

The pills, advertised as promoting weight loss, are distributed by a company called Xiushentang and sold on popular web sites including Amazon.com, said the FDA.

Consumers are advised to stop using the pills -- which are packaged in three colors: green, yellow and blue -- and discard them. They should also see a doctor if they have experienced any side effects, the agency said.

An FDA lab analysis has confirmed that the pills, "Japan Rapid Weight Loss Diet Pills Green" contain "undeclared phenolphthalein," the agency said in a statement.

"Phenolphthalein is a solution used in chemical experiments and a suspected cancer-causing agent that is not approved for marketing in the United States."

The FDA has classified the agent as "not generally recognized as safe and effective," and it has been found to potentially damage or even cause mutations in a person's DNA, the warning said.

A similar notice was issued for "Japan Rapid Weight Loss Diet Pills Yellow" because they contain both phenolphthalein and sibutramine, a weight loss agent found in the drug Meridia that was removed from the market in 2010 because it boosted the risk of heart attack and stroke.

"The product poses a threat to consumers because sibutramine is known to substantially increase blood pressure and/or in some patients and may present a significant risk for patients with a history of , , arrhythmias or stroke," the FDA said.

A third product, "Japan Weight Loss Blue" contains sibutramine and ephedrine alkaloids. Products containing ephedra have been banned because they can boost blood pressure to risky levels.

The agency said the dangerous weight loss pills are part of an emerging trend in which companies sell products purporting to be dietary supplements but which contain hidden ingredients that can be harmful.

add to favorites email to friend print save as pdf

Related Stories

FDA declines to approve Orexigen diet drug

Feb 01, 2011

(AP) -- Orexigen Therapeutics Inc. shares plunged nearly 75 percent in pre-market trading Tuesday after U.S. health officials declined to approve the experimental weight loss pill Contrave.

Experimental diet pill shows promise, little risk

Jul 14, 2010

(AP) -- An experimental diet pill helped about half the people who tried it lose some weight and keep it off a year later, without the heart problems that some earlier drugs caused, a study found.

FTC sues Arizona company over acai pill free trials

Aug 16, 2010

(AP) -- The Federal Trade Commission says an Arizona company defrauded consumers who signed up for free trials of acai (ah-sah-EE') berry weight-loss pills and colon cleansing supplements.

Recommended for you

No added benefit proven for umeclidinium/vilanterol in COPD

4 hours ago

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

Ebola vaccine not before late 2016: GSK researcher

Oct 17, 2014

An Ebola vaccine by British pharmaceuticals giant GlaxoSmithKline may not be ready for commercial use until late 2016 and should therefore not be seen as the "primary answer" to the current outbreak, a company researcher ...

Chimerix gets FDA OK to test drug for Ebola

Oct 17, 2014

(AP)—A North Carolina drugmaker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration.

Esbriet, ofev approved to treat deadly lung disease

Oct 16, 2014

(HealthDay)—Two new drugs have been approved by the U.S. Food and Drug Administration to treat progressive lung scarring from an uncertain cause, medically called idiopathic pulmonary fibrosis (IPF).

FDA weighs removing bolded warning from Chantix

Oct 14, 2014

(AP)—The Food and Drug Administration will ask a panel of experts later this week whether a bold-letter warning on the anti-smoking drug Chantix should be removed based on company-supported evidence that the drug does not ...

User comments